MARC details
| 000 -CABECERA |
| campo de control de longitud fija |
06930nam a2200349 c 4500 |
| 001 - NÚMERO DE CONTROL |
| campo de control |
115554 |
| 003 - IDENTIFICADOR DEL NÚMERO DE CONTROL |
| campo de control |
ESmaUEC |
| 005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN |
| campo de control |
20230110040236.0 |
| 006 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA--CARACTERÍSTICAS DEL MATERIAL ADICIONAL |
| campo de control de longitud fija |
a||||fo|||| 00| 0 |
| 007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA--INFORMACIÓN GENERAL |
| campo de control de longitud fija |
cr nn nnnaamaa |
| 008 - DATOS DE LONGITUD FIJA--INFORMACIÓN GENERAL |
| campo de control de longitud fija |
190617s2019 sz a o |||| 0|eng d |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
| Número Internacional Estándar del Libro |
9783034806206 |
| 024 7# - IDENTIFICADOR DE OTROS ESTÁNDARES |
| Número estándar o código |
10.1007/978-3-0348-0620-6 |
| Fuente del número o código |
doi |
| 040 ## - FUENTE DE LA CATALOGACIÓN |
| Centro catalogador/agencia de origen |
ES-MaUEC |
| Lengua de catalogación |
spa |
| Centro/agencia transcriptor |
ES-MaUEC |
| Centro/agencia modificador |
ES-MaUEC |
| 050 #4 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO |
| Número de clasificación |
RB131 |
| Número de documento/Ítem |
2019 EB |
| 245 00 - MENCIÓN DE TÍTULO |
| Título |
Compendium of Inflammatory Diseases |
| Mención de responsabilidad, etc. |
edited by Michael J. Parnham. |
| 264 #1 - PRODUCCIÓN, PUBLICACIÓN, DISTRIBUCIÓN, FABRICACIÓN Y COPYRIGHT |
| Producción, publicación, distribución, fabricación y copyright |
Basel |
| Nombre del de productor, editor, distribuidor, fabricante |
Springer Basel |
| Fecha de producción, publicación, distribución, fabricación o copyright |
2019 |
| 300 ## - DESCRIPCIÓN FÍSICA |
| Extensión |
1 recurso en línea (1600 páginas) |
| 336 ## - TIPO DE CONTENIDO |
| Término de tipo de contenido |
Texto |
| Código de tipo de contenido |
txt |
| Fuente |
rdacontent |
| 337 ## - TIPO DE MEDIO |
| Fuente |
rdamedia |
| Nombre/término del tipo de medio |
electrónico |
| Código del tipo de medio |
c |
| 338 ## - TIPO DE SOPORTE |
| Fuente |
rdacarrier |
| Nombre/término del tipo de soporte |
recurso electrónico |
| Código del tipo de soporte |
cr |
| 347 ## - CARACTERÍSTICAS DEL ARCHIVO DIGITAL |
| Tipo de archivo |
text file |
| Formato de codificación |
PDF |
| 490 0# - MENCIÓN DE SERIE |
| Mención de serie |
Biomedical and Life Sciences (Springer-11642) |
| 505 0# - NOTA DE CONTENIDO CON FORMATO |
| Nota de contenido con formato |
Adhesion molecules of neutrophils -- Anaphylaxis (Immediate hypersensitivity): from old to new mechanisms -- Antiviral Responses -- Autophagy and Inflammation -- Basophils -- Cell signalling in neutrophils -- Co-stimulatory Receptors -- Dendritic Cells -- GILZ-Related Regulation of Inflammation -- Glial Cells -- Immunoglobulin receptors and inflammation.-Inflammation and autoimmunity -- Inflammatory Bowel Disease Models in Animals -- Leukocyte Recruitment -- Lymphocyte homing and trafficking -- Macrophage heterogeneity during inflammation -- Mast Cells -- Mechanisms of Macrophage Migration in 3-Dimensional Environments -- Microvascular Responses to Inflammation -- Modulation of inflammation by key nutrials -- Natural Killer Cells -- Neutrophil Extracellular Traps -- Neutrophil oxidative burst -- Obesity and Inflammation -- Osteoclasts in Inflammation -- Parasitism: A Unique Lifestyle Reflecting Dynamic Parasite- and Host(s)-Co-driven Processes -- Platelet, Endothelium, and Inflammation -- Regulatory T cells -- Sepsis Models in Animals -- Skin inflammation models in animals -- Th17 Response -- Toll-Like Receptors -- Angiogenesis Inhibitors -- Anti-asthma Drugs, Overview -- Anti-histamines -- Anti-muscarinics -- Antibiotics as anti-inflammatory drugs -- Antimalarial Drugs -- Azathioprine/Thiopurines -- Beta2 Agonists -- CD 20 Inhibitors - Rituximab -- CD80/86 Inhibitors -- Chromones - Cromoglycate and Nedocromil -- Colony stimulating factor therapeutics -- Corticosteroids -- Coxibs -- Disease-Modifying Anti-Rheumatic Drugs -- Fenamates -- Flavonoids as anti-inflammatory agents -- Gold Complexes -- Interleukin 1 Inhibitors -- Interleukin 12/23 Inhibitors: Ustekinumab Interleukin-6 Inhibitor - Tocilizumab -- Leflunomide -- Medicinal Fatty Acids -- Methotrexate.-NO-donating anti-inflammatory drugs -- Non-steroidal anti-inflammatory drugs -- Phosphodiesterase-4 inhibitors -- Propionic Acid Derivative Drugs (Profens) -- Salicylates -- Sulfasalazine and Related Drugs -- Tetracyclines -- Theophylline -- TNF Inhibitors -- Acute exacerbations of airway inflammation -- Allergic Disorders -- Alzheimer's Disease -- Antiphospholipid antibody syndrome -- Asthma -- Atopic dermatitis -- Autoinflammatory syndromes -- Behcet's disease -- Bronchiolitis obliterans -- Cancer and inflammation -- Cogan's syndrome -- COPD -- Diabetes type I -- Diabetes type II -- Diffuse panbronchiolitis -- Gaucher's disease -- Genetic susceptibility to inflammatory diseases -- Gout -- Graft vs Host Disease -- Granulomatosis with Polyangiitis (GPA) -- Grave's disease.-Guillaine-Barre disease -- Henoch-Schönlein Purpura -- Idiopathic Thrombocytopenic Purpura -- Inflammatory bowel disease -- Juvenile idiopathic arthritis -- Kawasaki Disease -- Lyme disease -- Osteoarthritis.-Osteoarthritis Genetics -- Polymyositis and Dermatomyositis -- Rheumatic Fever -- Rheumatoid arthritis -- Role of Cell Therapy in Autoimmune Disease -- Sarcoidosis -- Sepsis -- Spondylarthropathies -- ACKR3 -- Adhesion molecules -- Alarmins -- Antibacterial Host .-Defense Peptides -- Bacterial Lipopolysaccharide.-Biofilm -- Bone Morphogenetic Proteins in Inflammation -- C5a Receptors -- CCL18 -- CCR1 -- Ceramide 1-Phosphate: A Mediator of Inflammatory Responses -- Complement System -- CXCL4 und CXCL4L1 -- CXCR1 and CXCR2 and Ligands -- CXCR3 and its Ligands -- Cytokines -- Cytolytic Granules -- Foxp3 -- Heat Shock Proteins -- Histamine -- IFNgamma -- IkappaB -- Inflammasomes -- Interleukin 1 -- Interleukin 10 -- Interleukin 12 -- Interleukin 17 -- Interleukin 18 -- Interleukin 18 Binding Protein -- Interleukin 2 -- Interleukin 22 -- Interleukin 23 -- Interleukin 27 -- Interleukin 32 -- Interleukin 36 Cytokines -- Interleukin 4 and the related cytokines (Interleukin 5 and Interleukin 13) -- Interleukin 6 -- Interleukin 9 -- Interleukin-33 -- Janus Kinases (JAKs)/STAT Pathway -- Kinins -- Leukotrienes -- Mammalian Target of Rapamycin (mTOR) -- MAP Kinase Pathways -- NFkappaB -- Nitric oxide -- Nuclear Receptor Signaling in the Control of Inflammation -- Pathogen-Associated Molecular Patterns (PAMPs) -- Pentraxins -- Prostanoids -- Protease-Activated Receptors -- Reactive oxygen species -- Substance P in Inflammation -- TGF-b superfamily cytokine MIC-1/GDF15 in health and inflammatory diseases -- TNFalpha -- Type I Interferons. |
| 520 3# - SUMARIO, ETC. |
| Sumario, etc. |
Inflammation has become one of the most exciting and rewarding areas of medical research. Recent years have seen a revolution in our understanding of how blood and tissue cells interact and of the intracellular mechanisms controlling their activation. This has revealed the underlying inflammatory pathology of many diseases and provided multiple new targets for anti-inflammatory and immunomodulatory therapy. The Encyclopedia of Inflammatory Diseases will cover the following areas: Inflammatory Processes and Cells Inflammatory Diseases Mediators of Inflammation Pharmacology of Inflammation Since inflammatory diseases and their therapy cover a broad range of scientific and medical fields, the encyclopedia will be co-edited by four international experts, a clinician and three researchers from the disciplines of immunology, biochemistry, and pharmacology, in this way providing students, basic and clinical scientists and practitioners in academia, hospitals and industry with valuable interlinked information. This living project will serve as a reliable and comprehensive data pool for everybody working in inflammation research. Owing to its dynamic nature, it will grow with time and future editions, becoming an indispensible source of information for academia, clinical practitioners and industry. |
| 650 #7 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
| Fuente del encabezamiento o término |
embne |
| Término de materia o nombre geográfico como elemento de entrada |
Inflamación |
| 9 (RLIN) |
153270 |
| 700 1# - PUNTO DE ACCESO ADICIONAL--NOMBRE DE PERSONA |
| Nombre de persona |
Parnham, Michael J |
| Término indicativo de función/relación |
editor |
| Código de función/relación |
http://id.loc.gov/vocabulary/relators/edt |
| 9 (RLIN) |
100348 |
| 856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS |
| Identificador Uniforme del Recurso |
https://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-0348-0620-6 |
| Nota pública |
Acceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 988 ## - NOTA LOCAL 598 |
| Nota local 598 |
Springer_BiomedLife_2019 |
| 999 ## - NÚMEROS DE CONTROL DE SISTEMA (KOHA) |
| -- |
1 |
| 942 ## - ELEMENTOS DE PUNTO DE ACCESO ADICIONAL (KOHA) |
| Fuente del sistema de clasificación o colocación |
Library of Congress Classification |
| Tipo de ítem Koha |
LIBRO-E NO PRÉSTAMO |
| 998 ## - FONDO MILLENIUM |
| Biblioteca |
SI |
| Tipo de registro |
m |
| Tipo de materia |
z |
| Idioma |
eng |
| País |
gw |
| h |
0 |
| Fecha creación |
12/2019 |
| e |
k |
| Catalogado |
Sí |